Compagnie Lombard Odier SCmA Raises Holdings in AbbVie Inc. $ABBV

Compagnie Lombard Odier SCmA lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 322,464 shares of the company’s stock after purchasing an additional 16,262 shares during the period. Compagnie Lombard Odier SCmA’s holdings in AbbVie were worth $73,680,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the second quarter valued at approximately $26,000. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter valued at $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the 3rd quarter valued at $31,000. Finally, Caitlin John LLC purchased a new stake in AbbVie in the 3rd quarter valued at $33,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on ABBV shares. Piper Sandler raised their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Royal Bank Of Canada assumed coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. Finally, UBS Group reduced their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.15.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Federal tax-law effects: Analysts and reports show U.S. corporate cash taxes fell roughly $65B after recent tax changes, a trend benefiting large pharma cash flow and near-term free cash flow for companies like AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Positive Sentiment: Allergan Aesthetics promotion: AbbVie’s aesthetics unit is running its fourth annual CoolMonth promotion (CoolSculpting offers), which can modestly boost procedure volumes and near-term aesthetics revenue. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
• Neutral Sentiment: Earnings schedule: AbbVie set its Q1 2026 results release and conference call for April 29 (pre-market), a scheduled event that will be the next major catalyst for stock direction. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Mixed intraday moves: Recent headlines show short-term intraday swings (some sessions with gains, others with underperformance versus the market), indicating investor attention is currently fragmented between fundamentals and newsflow. AbbVie Inc. stock rises Tuesday, still underperforms market AbbVie (ABBV) Gains As Market Dips: What You Should Know
• Negative Sentiment: Litigation tied to Cerevel/AbbVie deal: A court ordered Pfizer and Bain to litigate a suit by Cerevel investors over the AbbVie transaction, creating deal-related legal uncertainty and potential distraction or liabilities. That legal cloud can pressure sentiment around transactions and M&A strategy. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Oncology headwinds: Analyst commentary flags likely 2026 revenue pressure in AbbVie’s oncology franchise — pricing pressure on Imbruvica and a near-term dip in legacy oncology sales could offset growth from newer oncology assets. This is a direct revenue-risk item investors care about for 2026 guidance. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?

AbbVie Price Performance

ABBV opened at $214.72 on Thursday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market capitalization of $379.66 billion, a P/E ratio of 90.98, a P/E/G ratio of 0.76 and a beta of 0.38. The business has a 50 day simple moving average of $221.98 and a 200-day simple moving average of $224.58.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the business posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.